Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [m6A-seq]

ABSTRACT: IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [m6A-seq]

PROVIDER: PRJNA1062722 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27467613_1.fastq.gz	Fastqsanger.gz
	SRR27467613_2.fastq.gz	Fastqsanger.gz
	SRR27467614_1.fastq.gz	Fastqsanger.gz
	SRR27467614_2.fastq.gz	Fastqsanger.gz
	SRR27467615_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [m6A-seq]

Project description:We report a previously unrecognized role of IGF2BP3 in survival of neuroblastoma cells. To explore IGF2BP3-dependent gene regulation and m6A modification, RNA-seq and m6A-seq analysis was conducted and the differently expressed/modified genes were revealed in the IGF2BP3-knockdown SK-N-BE(2) cells in comparison to control group.

2024-12-31 | GSE252796 | GEO

IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [RNA-seq]

Project description:IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [RNA-seq]

| PRJNA1062723 | ENA

IGF2BP3 mediates m6A-modified E2F2 stability to affect neuroblastoma progression [RNA-seq]

2024-12-31 | GSE252797 | GEO

Potential Roles of IGF2BP3 in Bladder Cancer [m6A-seq]

Project description:TCGA data analysis and clinical sample test results showed the IGF2BP3 is highly expressed in bladder cancer and related to tumor metastasis and invasion. RNA sequencing results of clinical bladder tissue from 53 cases showed that the IGF2BP3 expression is related to cell proliferation genes. M6a and RNA sequencing results showed the IGF2BP3 affects the growth, proliferation, and apoptosis of T24 cells, and SpHK1, POMT2, and MRPS18a may be potential targets of IGF2BP3.

2024-03-27 | GSE171023 | GEO

IGF2BP3 promotes mRNA degradation through internal m7G modification [seq_Ribo]

Project description:Recent studies have suggested that mRNA internal m7G and its writer protein METTL1 are closely related to cell metabolism and cancer regulation. Here, we identify that IGF2BP family proteins IGF2BP1-3 can preferentially bind internal mRNA m7G. Such interactions, especially IGF2BP3 with m7G, could promote the degradation of m7G target transcripts in cancer cells. IGF2BP3 is more responsive to changes of the m7G modification, while IGF2BP1 prefers m6A to stabilize the bound transcripts. We also demonstrate that p53 transcript, TP53, is m7G-modified at its 3’UTR in cancer cells. In glioblastoma, the methylation level and the half lifetime of the modified transcript could be modulated by tuning IGF2BP3, or by site-specific targeting of m7G through a dCas13b-guided system, resulting in modulation of cancer progression and chemosensitivity.

2024-07-15 | GSE269962 | GEO

IGF2BP3 promotes mRNA degradation through internal m7G modification [PARCLIP]

2024-07-15 | GSE266130 | GEO

IGF2BP3 promotes mRNA degradation through internal m7G modification [MeRIP-Seq]

2024-07-15 | GSE241149 | GEO

IGF2BP3 promotes mRNA degradation through internal m7G modification [RNA-Seq]

2024-07-15 | GSE241147 | GEO

KIAA1429/VIRMA promotes breast cancer proliferation and migration by stabilizing m6A-modified HAS2 RNA expression in cytosol

Project description:N6-methyladenosine (m6A) is the most abundant internal RNA modification in mRNA molecules and plays important roles in multiple important biological processes including cancer development. KIAA1429/VIRMA is an important component of m6A methyltransferase complex to facilitate depositing m6A modification in RNA molecules. Here we found that KIAA1429/VIRMA was overexpressed in breast cancer patients among other m6A related enzymes. Breast cancer patients with higher KIAA1429 expression have worse survival compared with control group. In addition, KIAA1429/VIRMA protein mislocated in cytosol in breast cancer tissues and cell lines. KIAA1429/VIRMA depletion reduced breast cancer cell proliferation and migration. Mechanism studies showed that cytosolic expressed KIAA1429/VIRMA interacted with m6A reader protein IGF2BP3 and stabilized expression of m6A-modified HAS2 expression. HAS2 is downstream of KIAA1429/VIRMA to mediate breast cancer cell proliferation and migration and has positive correlation with KIAA1429/VIRMA expression in cancer patients.

2021-11-02 | GSE185494 | GEO

m6A-modified CBX1 regulates NPC progression.

Project description:m6A-modified CBX1 regulates NPC progression.

| PRJNA826827 | ENA